Vibegron

Vibegron
Clinical data
Trade namesGemtesa
Other namesKRP-114V, MK-4618, RVT-901, URO-901
AHFS/Drugs.comMonograph
License data
Routes of
administration		By mouth
Drug classBeta3 adrenergic receptor agonist
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding49.6 to 51.3% is bound to plasma proteins [4]
MetabolismPredominantly oxidation and glucuronidation [4]
Elimination half-life60 to 70 hours [4]
Excretion59% feces (54% of this is in the unchanged parent drug form), 20% urine (19% of this is in the unchanged parent drug form)[1]
Identifiers
  • (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.547 Edit this at Wikidata
Chemical and physical data
FormulaC26H28N4O3
Molar mass444.535 g·mol−1
3D model (JSmol)
  • O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21
  • InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
  • Key:DJXRIQMCROIRCZ-XOEOCAAJSA-N

Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder.[1][5][6] Vibegron is a selective beta-3 adrenergic receptor agonist.[1]

The most common side effects include headache, urinary tract infection, common cold, diarrhea, nausea, and upper respiratory tract infection.[5]

Vibegron was first discovered by scientists at Merck & Co. Inc.[7] and was later developed in Japan by Kyorin Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd, and Urovant Sciences.[8] It was approved for medical use in Japan in September 2018,[8] in the United States in December 2020,[1][5][6] and in the European Union in June 2024.[2]

  1. ^ a b c d e "Gemtesa- vibegron tablet, film coated". DailyMed. Archived from the original on 14 January 2021. Retrieved 12 January 2021.
  2. ^ a b Cite error: The named reference Obgemsa EPAR was invoked but never defined (see the help page).
  3. ^ "Obgemsa PI". Union Register of medicinal products. 28 June 2024. Retrieved 5 July 2024.
  4. ^ a b c Cite error: The named reference Rechberger_2021 was invoked but never defined (see the help page).
  5. ^ a b c "Drug Trials Snapshot: Gemtesa". U.S. Food and Drug Administration (FDA). 23 December 2020. Archived from the original on 12 January 2021. Retrieved 12 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ a b "Sumitovant Biopharma Announces Urovant Sciences Receives U.S. FDA Approval of Gemtesa (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)" (Press release). Sumitovant Biopharma. 23 December 2020. Archived from the original on 5 July 2024. Retrieved 23 December 2020 – via GlobeNewswire.
  7. ^ US8247415B2 https://patents.google.com/patent/US8247415
  8. ^ a b Keam SJ (November 2018). "Vibegron: First Global Approval". Drugs. 78 (17): 1835–1839. doi:10.1007/s40265-018-1006-3. PMID 30411311. S2CID 53212220.